Arctoris was featured in an article by Nanalyze examining the growing role of automation in life sciences laboratories. The piece explores how robotic experimentation and automated laboratory platforms are transforming drug discovery by enabling faster, more reproducible research.
As pharmaceutical R&D becomes increasingly data-driven, laboratory automation allows scientists to run experiments at greater scale and with improved consistency. Platforms that integrate robotics, software, and scientific expertise can accelerate hypothesis testing and the generation of high-quality experimental datasets.
In the article, Nanalyze highlights Arctoris as an example of a company enabling this shift through automated experimentation infrastructure. Such platforms can support computational and AI-driven drug discovery companies by providing a reliable way to test hypotheses and generate experimental validation.
All of the AI drug discovery companies we’ve looked at… would be potential users of the Arctoris platform to test new hypotheses, collect data, and progress projects from in vitro to in vivo testing.
Automation platforms like Arctoris’ Ulysses® system enable researchers to conduct complex biological experiments with high precision, reproducibility, and scalability. This capability is increasingly important as computational approaches generate large numbers of hypotheses that require rapid experimental validation.